GEN-002 Plus Avelumab Shows Promise as Third-line Option in PD-L1+ Gastric Cancer
The combination of GEN-002 and avelumab elicited responses in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from an interim analysis of an ongoing phase 2 trial.
South Korea Jeeyun Lee Genome Company Oncology Division At Samsung Medical Center Korea Ministry Of Food Oncology Division
Source: onclive.com